Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: OBIO

Orchestra BioMed Holdings, Inc.

Healthcare | Biotechnology

No licensed closing price on file for OBIO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.83

Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 02:48 UTC.

What Orchestra BioMed Holdings, Inc. does

Orchestra BioMed is a biomedical innovation company formed to advance late-stage medical device technologies through partnerships with leading device manufacturers. The company's flagship candidate, AVIM Therapy, is a bioelectronic treatment for high blood pressure that integrates into cardiac pacemakers and is being developed with Medtronic under an exclusive license agreement; a global pivotal study called BACKBEAT is currently enrolling patients. The company's second major product, Virtue SAB, is a drug-coated balloon designed to treat blocked arteries and is in a U.S.

Summarized from Orchestra BioMed Holdings, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.83

Revenue, margins & earnings

FY2022: net loss $34M on revenue $4M$4MFY2022FY2023: net loss $49M on revenue $3M$3MFY2023FY2024: net loss $61M on revenue $3M$3MFY2024FY2025: net loss $53M on revenue $33M$33MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-02
  • 2026-10-02See RemarksSale-15,000$95.4K
  • 2026-09-11See RemarksTax withholding-3,283$19.1K
  • 2026-09-11See RemarksTax withholding-3,283$19.1K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Orchestra BioMed Holdings, Inc. do?

Orchestra BioMed is a biomedical innovation company formed to advance late-stage medical device technologies through partnerships with leading device manufacturers.

When did OBIO last file with the SEC?

Orchestra BioMed Holdings, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-23. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 02:48 UTC. This page is also available as JSON at /api/data?ticker=OBIO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for OBIO and 5,000+ tickers.

Create a free account — keep OBIO
For your agent
GET /api/data?ticker=OBIO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt